NasdaqGS:PCVXBiotechs
OPUS-3 Launch and Broad VAX-31 Program Could Be A Game Changer For Vaxcyte (PCVX)
Vaxcyte recently reported that it has begun dosing participants in OPUS-3, a Phase 3 trial of its 31-valent pneumococcal conjugate vaccine VAX-31 in adults who were previously vaccinated, as part of a broader Phase 3 program aligned with the U.S. FDA to support a future Biologics License Application.
An interesting angle for investors is that VAX-31, which holds Breakthrough Therapy designation and is described as the broadest-spectrum pneumococcal conjugate vaccine in the clinic, is being...